Are you Dr. Prajapati?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 1 invite waiting! - Read the latest clinical news, personalized to your specialty.
Office
300 Longwood Ave
Dermatology Program
Boston, MA 02115Phone+1 617-580-1982
Summary
- Dr. Vimal Prajapati, MD is a board certified dermatologist in Boston, Massachusetts. He is currently licensed to practice medicine in Massachusetts.
Certifications & Licensure
- MA State Medical License 2013 - 2014
- American Board of Dermatology Dermatology
- American Board of Dermatology Pediatric Dermatology
Publications & Presentations
PubMed
- Real-World Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-23 Inhibitors: A Multicenter Retrospective Study.Siddhartha Sood, Alexander Rimke, Brian D Rankin, Abrahim Abduelmula, Jorge R Georgakopoulos
American Journal of Clinical Dermatology. 2025-03-01 - Efficacy and Safety of Once-Daily Roflumilast Cream 0.05% in Pediatric Patients Aged 2-5 Years With Mild-to-Moderate Atopic Dermatitis (INTEGUMENT-PED): A Phase 3 Rand...Lawrence F Eichenfield, Rocco Serrao, Vimal H Prajapati, John C Browning, Lisa Swanson
Pediatric Dermatology. 2025-02-20 - Management of Chronic Prurigo and Prurigo Nodularis with Systemic Janus Kinase Inhibitors: An Evidence-Based Review.Siddhartha Sood, Ryan S Q Geng, Martin Heung, Khalad Maliyar, Abrahim Abduelmula
Journal of Cutaneous Medicine and Surgery. 2025-02-15
Press Mentions
- New Teen Psoriasis TreatmentJanuary 22nd, 2016
- Study: Upadacitinib Produces Sustained Improvements in 140 WeeksJune 19th, 2024